Identification of Relaxin Receptor Antagonists
松弛素受体拮抗剂的鉴定
基本信息
- 批准号:6947202
- 负责人:
- 金额:$ 21.54万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2004
- 资助国家:美国
- 起止时间:2004-09-10 至 2006-08-31
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
DESCRIPTION (provided by applicant): Relaxin is a heterodimeric peptide hormone produced by the corpus luteum, decidua, and placenta in pregnant and nonpregnant females attaining the highest plasma levels during pregnancy. Other than its role in the inhibition of uterine contractile activity, relaxin has been shown to effect the induction of collagen remodeling and the consequent softening of the tissues of the birth canal (cervix and vagina), growth and differentiation of the mammary gland, and dilation of the blood vessels. Thus, relaxin plays a significant role in the overall regulation of physiological adaptation during pregnancy. Based on: primary and secondary structural characteristics, relaxin was grouped with insulin and insulin-like growth factors (IGFs) as a structural homolog. Analogous to insulin, prorelaxin, the precursor form of relaxin, has a domain arrangement similar to insulin and IGF precursors; mature relaxin appears to be processed by convertases to generate a two-chain heterodimer from the prorelaxin. In addition to two almost identical relaxin genes in human, there are five additional relaxin family genes including those encoding INSL3/RLF, INSIA/EPIL, INSL5/RIF2, INSL6/RIF1, and relaxin3. Passive immunization with anti-relaxin antibodies during the anteparmm period reduces cervical growth and extensibility as well as disrupts birth in rodents. In addition, numerous studies have shown that serum relaxin is an independent predictor of the risk of preterm delivery at multiple stages of pregnancy in humans. These earlier studies have propelled the proposition that a reduction of relaxin activity through receptor antagonists or immunization could be important for the treatment of preterm labor and birth in conjunction with traditional methods targeting other signaling pathways. Our recent studies have established that relaxin activates two orphan G protein-coupled receptors, LGR7 and LGR8 (Hsu et al., 2002. Science 295:671-4) as well as the cAMP-dependent pathway in target cells, whereas the closely related relaxin3 and INSL3 are selective agonists for LGR7 and LGR8, respectively. To take advantage of these new findings in relaxin signaling for the benefit of reproductive health research, we propose to screen for mutant recombinant relaxin antagonists that retain receptor-binding activity while being devoid of receptor-activation activity. Once mutant peptides with only the receptor binding activity are obtained, the antagonistic effect of these peptides will be tested in co-treatment assays to determine whether the mutant peptides are capable of antagonizing the relaxin-induced cAMP production in LGR7- and LGR8- expressing cells as well as delaying parturition in pregnant rats in vivo. These antagonists could be used to block relaxin action during preterm labor as well as provide a tool for further research on the role of LGR7 and LGR8 in reproductive tract physiology.
描述(由申请人提供):松弛素是一种异二聚肽激素,由怀孕和非怀孕女性的黄体、蜕膜和胎盘产生,在怀孕期间达到最高血浆水平。除了抑制子宫收缩活动外,松弛素还被证明可以诱导胶原蛋白重塑,从而导致产道组织(子宫颈和阴道)软化、乳腺生长和分化以及扩张。的血管。因此,松弛素在怀孕期间生理适应的整体调节中起着重要作用。基于:一级和二级结构特征,松弛素与胰岛素和胰岛素样生长因子(IGF)作为结构同源物分组。与胰岛素类似,松弛素前体(松弛素的前体形式)具有与胰岛素和 IGF 前体相似的结构域排列;成熟的松弛素似乎被转化酶加工以从松弛素原产生双链异二聚体。除了人类中两个几乎相同的松弛素基因外,还有另外五个松弛素家族基因,包括编码 INSL3/RLF、INSIA/EPIL、INSL5/RIF2、INSL6/RIF1 和relaxin3 的基因。 在分娩前使用抗松弛素抗体进行被动免疫会降低宫颈生长和伸展性,并扰乱啮齿类动物的出生。此外,大量研究表明,血清松弛素是人类妊娠多个阶段早产风险的独立预测因子。这些早期研究提出了这样的观点:通过受体拮抗剂或免疫降低松弛素活性,结合针对其他信号通路的传统方法,对于治疗早产和分娩可能很重要。我们最近的研究已经证实,松弛素激活两个孤儿 G 蛋白偶联受体 LGR7 和 LGR8(Hsu 等人,2002. Science 295:671-4)以及靶细胞中的 cAMP 依赖性途径,而密切相关的relaxin3 和 INSL3 分别是 LGR7 和 LGR8 的选择性激动剂。为了利用松弛素信号传导方面的这些新发现来促进生殖健康研究,我们建议筛选突变重组松弛素拮抗剂,这些拮抗剂保留受体结合活性,同时缺乏受体激活活性。一旦获得仅具有受体结合活性的突变肽,将在共治疗测定中测试这些肽的拮抗作用,以确定突变肽是否能够拮抗LGR7和LGR8表达细胞中松弛素诱导的cAMP产生以及延迟怀孕大鼠体内的分娩。这些拮抗剂可用于阻断早产期间松弛素的作用,并为进一步研究 LGR7 和 LGR8 在生殖道生理学中的作用提供工具。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
SHEAU-YU Teddy HSU其他文献
SHEAU-YU Teddy HSU的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('SHEAU-YU Teddy HSU', 18)}}的其他基金
Developing Novel Therapies for Treating Breast-Cancer-Related Lymphedema
开发治疗乳腺癌相关淋巴水肿的新疗法
- 批准号:
8647758 - 财政年份:2014
- 资助金额:
$ 21.54万 - 项目类别:
Prevention of Preeclampsia-associated preterm births
预防先兆子痫相关的早产
- 批准号:
8780971 - 财政年份:2014
- 资助金额:
$ 21.54万 - 项目类别:
Role of RAMPs in Intermedin Signaling
RAMP 在 Intermedin 信号转导中的作用
- 批准号:
7771528 - 财政年份:2006
- 资助金额:
$ 21.54万 - 项目类别:
Role of RAMPs in Intermedin Signaling
RAMP 在 Intermedin 信号转导中的作用
- 批准号:
7437340 - 财政年份:2006
- 资助金额:
$ 21.54万 - 项目类别:
Role of RAMPs in Intermedin Signaling
RAMP 在 Intermedin 信号转导中的作用
- 批准号:
7147883 - 财政年份:2006
- 资助金额:
$ 21.54万 - 项目类别:
Role of RAMPs in Intermedin Signaling
RAMP 在 Intermedin 信号转导中的作用
- 批准号:
7258366 - 财政年份:2006
- 资助金额:
$ 21.54万 - 项目类别:
Role of RAMPs in Intermedin Signaling
RAMP 在 Intermedin 信号转导中的作用
- 批准号:
7636767 - 财政年份:2006
- 资助金额:
$ 21.54万 - 项目类别:
相似国自然基金
氮同位素约束的海洋固氮与输出生产力耦合关系研究
- 批准号:42376140
- 批准年份:2023
- 资助金额:51 万元
- 项目类别:面上项目
孕期夜光暴露对新生儿出生体重的影响及其通过褪黑素调节胎盘mTOR信号通路的机制研究
- 批准号:82373536
- 批准年份:2023
- 资助金额:49 万元
- 项目类别:面上项目
出生后酮体生成对成年期卵子发育和后代健康的作用及机制研究
- 批准号:82330050
- 批准年份:2023
- 资助金额:220 万元
- 项目类别:重点项目
热分层环境中运动状态下人呼出生物气溶胶在呼出气流与迎面气流耦合下的传输机制研究
- 批准号:52308103
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
利用基因敲除小鼠研究大麻素受体信号调控生长板软骨内骨化及出生后长骨生长的相关机制
- 批准号:82302658
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
相似海外基金
Therapeutic Potential of Rescued FMR1 Mis-Splicing in Fragile X Syndrome
挽救 FMR1 错误剪接对脆性 X 综合征的治疗潜力
- 批准号:
10713600 - 财政年份:2023
- 资助金额:
$ 21.54万 - 项目类别:
Evaluating Human Pluripotent Stem Cell-Derived Neural Rosette Arrays as a Neural Tube Defect Risk Screening Platform
评估人类多能干细胞衍生的神经花环阵列作为神经管缺陷风险筛查平台
- 批准号:
10218408 - 财政年份:2021
- 资助金额:
$ 21.54万 - 项目类别:
Evaluating Human Pluripotent Stem Cell-Derived Neural Rosette Arrays as a Neural Tube Defect Risk Screening Platform
评估人类多能干细胞衍生的神经花环阵列作为神经管缺陷风险筛查平台
- 批准号:
10369044 - 财政年份:2021
- 资助金额:
$ 21.54万 - 项目类别:
Age-related olfactory loss: mechanisms and treatment options
与年龄相关的嗅觉丧失:机制和治疗选择
- 批准号:
8786272 - 财政年份:2014
- 资助金额:
$ 21.54万 - 项目类别: